Skip to content
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article Psychedelic Company Highlights in 2021

Psychedelic Company Highlights in 2021

  • Post published:January 20, 2022
  • Post category:Analysis
Read more about the article Psychedelic Research and Clinical Trials in 2021

Psychedelic Research and Clinical Trials in 2021

  • Post published:January 10, 2022
  • Post category:Analysis
Read more about the article Psychedelic Drug Policy Reform in 2021

Psychedelic Drug Policy Reform in 2021

  • Post published:January 5, 2022
  • Post category:Analysis
Read more about the article Psychedelics 2021: A Year in Review

Psychedelics 2021: A Year in Review

  • Post published:January 5, 2022
  • Post category:Analysis
Read more about the article Preparing for COMPASS Pathways’ Phase Data Readout: 2b, or not to be?

Preparing for COMPASS Pathways’ Phase Data Readout: 2b, or not to be?

  • Post published:November 5, 2021
  • Post category:Analysis/News
Read more about the article Harvard Law School’s Petrie-Flom Center Launches Research Initiative on Psychedelics and the Law

Harvard Law School’s Petrie-Flom Center Launches Research Initiative on Psychedelics and the Law

  • Post published:June 30, 2021
  • Post category:Analysis/News
Read more about the article MagicMed to Be Acquired by Nasdaq-Listed Company

MagicMed to Be Acquired by Nasdaq-Listed Company

  • Post published:May 24, 2021
  • Post category:Analysis/News
Read more about the article Numinus Deep Dive: Developing and Delivering Psychedelic-Assisted Psychotherapies

Numinus Deep Dive: Developing and Delivering Psychedelic-Assisted Psychotherapies

  • Post published:March 23, 2021
  • Post category:Analysis/Editorial
Read more about the article Experiential Psilocybin-assisted Therapy Training Program, Approved by Health Canada, Gets Underway

Experiential Psilocybin-assisted Therapy Training Program, Approved by Health Canada, Gets Underway

  • Post published:March 2, 2021
  • Post category:Analysis/News
Read more about the article Tryp Therapeutics Launches Clinical Trials to Investigate Psilocybin for Over-Eating Disorders

Tryp Therapeutics Launches Clinical Trials to Investigate Psilocybin for Over-Eating Disorders

  • Post published:February 16, 2021
  • Post category:Analysis/Editorial

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More